These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22180752)

  • 21. Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism.
    Dufrasne FE; Lombard C; Goubau P; Ruelle J
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27754450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-Throughput NanoBiT-Based Screening for Inhibitors of HIV-1 Vpu and Host BST-2 Protein Interaction.
    Li B; Dong X; Zhang W; Chen T; Yu B; Zhao W; Yang Y; Wang X; Hu Q; Wang X
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cloning and characterization of the antiviral activity of feline Tetherin/BST-2.
    Fukuma A; Abe M; Morikawa Y; Miyazawa T; Yasuda J
    PLoS One; 2011 Mar; 6(3):e18247. PubMed ID: 21479233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
    Kueck T; Neil SJ
    PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
    Mitchell RS; Katsura C; Skasko MA; Fitzpatrick K; Lau D; Ruiz A; Stephens EB; Margottin-Goguet F; Benarous R; Guatelli JC
    PLoS Pathog; 2009 May; 5(5):e1000450. PubMed ID: 19478868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu.
    Andrew AJ; Miyagi E; Kao S; Strebel K
    Retrovirology; 2009 Sep; 6():80. PubMed ID: 19737401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dimerization of the transmembrane domain of human tetherin in membrane mimetic environments.
    Cole G; Simonetti K; Ademi I; Sharpe S
    Biochemistry; 2012 Jun; 51(25):5033-40. PubMed ID: 22667354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
    Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
    PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
    Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
    J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HM1.24/BST-2 is constitutively poly-ubiquitinated at the N-terminal amino acid in the cytoplasmic domain.
    Fujimoto K; Nakashima S; Uchida S; Amen RNS; Ishii Y; Hirota Y; Tanaka Y
    Biochem Biophys Rep; 2020 Sep; 23():100784. PubMed ID: 32715103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ebolavirus Replication and Tetherin/BST-2.
    Yasuda J
    Front Microbiol; 2012; 3():111. PubMed ID: 22485110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression.
    Dotson D; Woodruff EA; Villalta F; Dong X
    J Biol Chem; 2016 Feb; 291(8):4236-46. PubMed ID: 26742839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.
    Mack K; Starz K; Sauter D; Langer S; Bibollet-Ruche F; Learn GH; Stürzel CM; Leoz M; Plantier JC; Geyer M; Hahn BH; Kirchhoff F
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action.
    Skasko M; Tokarev A; Chen CC; Fischer WB; Pillai SK; Guatelli J
    Virology; 2011 Mar; 411(1):65-77. PubMed ID: 21237475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transmembrane interactions of HIV-1 Vpu and tetherin.
    Guo F; Liang C
    Curr HIV Res; 2012 Jun; 10(4):292-7. PubMed ID: 22524177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BST-2/tetherin: structural biology, viral antagonism, and immunobiology of a potent host antiviral factor.
    Swiecki M; Omattage NS; Brett TJ
    Mol Immunol; 2013 Jun; 54(2):132-9. PubMed ID: 23274150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
    Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
    mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells.
    Jolly C; Booth NJ; Neil SJ
    J Virol; 2010 Dec; 84(23):12185-99. PubMed ID: 20861257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct internalization of cell-surface BST-2/tetherin by the HIV-1 accessory protein Vpu.
    Iwabu Y; Fujita H; Tanaka Y; Sata T; Tokunaga K
    Commun Integr Biol; 2010 Jul; 3(4):366-9. PubMed ID: 20798829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.